HDL cholesterol treatment key to cardiovascular disease

Identifying treatments that modify HDL cholesterol levels is likely to be the future for cardiovascular disease (CVD) medicine, a leading heart expert has suggested.

Professor Jacques Genest, from McGill University in Montreal, Canada, told delegates at the European Society of Cardiology conference in Munich this week that the focus would shift to HDL, the ‘good’ cholesterol.

He said: ‘Some patients have very low levels of HDL because of genetic defects. Understanding the genes that regulate HDL metabolism may lead to novel therapeutic approaches.’

But Professor Genest warned that it was it had not yet been shown that increasing HDL with drugs could decrease the risk of CVD.


European Society of Cardiology conference Munich 2008

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in